A major rift has emerged across the United Kingdom healthcare landscape as regional health authorities clash over the future of national medical data architecture. While health officials across England have begun integrating software developed by American technology firm Palantir into hospital systems, the regional care board for Greater Manchester has repeatedly declined to adopt the platform. The regional authority has chosen instead to maintain its own locally engineered system, which was developed over nearly ten years. This decision by Greater Manchester NHS leadership has added momentum to a national political debate over whether the UK government should exercise an early termination clause in February next year to end its multi-year agreement with Palantir, rather than letting the contract run through 2031.
Fragmented Records and the Creation of the Federated Data Platform
For several decades, workers throughout the National Health Service (NHS) relied on a disjointed combination of digital programs, basic spreadsheets, physical paper files, and dry-erase whiteboards to monitor patient trajectories. When individuals transferred between care facilities or clinics, critical medical records frequently failed to follow them. In some instances, missing records led to severe or even fatal clinical errors. Furthermore, the absence of a unified data-sharing infrastructure forced health service managers to allocate funding and operational resources based on incomplete and fragmented information pools.
To resolve these longstanding administrative issues, the UK government commissioned Palantir in 2023 to construct a centralized Federated Data Platform (FDP). The system was designed to combine disparate health information streams across the country into a single structured ecosystem. Official implementation of the platform started in early 2024. The architecture consists of a primary national data pool to identify systemic care gaps, alongside localized databases where regional organizations can build targeted software tools for tasks such as surgical scheduling, waitlist management, and hospital discharge planning.
The underlying technical framework is designed to allow software tools created in one regional facility to be transferred seamlessly to another care setting across the nation. Independent IT consultant Tom Bartlett, who previously managed the national FDP implementation as deputy director of data engineering at NHS England, noted that the real power of the system lies in its ability to lift and shift tools while providing a unified environment for artificial intelligence processing.
National Adoption Metrics and Greater Manchester’s Solitary Stance
Within the broader structure of the NHS, access to data platforms is split between hospital trusts that manage direct clinical care and Integrated Care Boards (ICBs) responsible for regional service planning and commissioning. Government statistics reveal that 139 out of approximately 200 hospital trusts are currently live with Palantir technology. Additionally, 35 out of 36 ICBs across England are actively operating on the FDP infrastructure. Representatives from the Department of Health and Social Care have stated that thousands of additional patients receive direct care benefits from the software every month, pointing to reductions in wait times, shorter hospital stays, and improved utilization of operating rooms.
Despite widespread adoption across England, health organizations in Greater Manchester have resisted full integration. Researchers at Health Innovation Manchester, including chief digital and data officer Andy Haywood, indicate that local hospital trusts are utilizing the platform for only restricted tasks rather than routing all regional data through it. More significantly, the Integrated Care Board for Greater Manchester, which oversees health services for a regional population of approximately 3 million people, remains the only care board in England to formally refuse the FDP.
Inside Greater Manchester’s In-House ADSP Alternative
Rather than adopting the national software package, Greater Manchester has relied on its custom-built Analytics and Data Science Platform (ADSP). During a formal meeting in May 2025, despite strong encouragement from national NHS leadership to align with the national platform, the Greater Manchester ICB determined that its local technological capabilities surpassed what the national system currently provided. Board evaluations concluded that certain features of their in-house platform were two to three years ahead of the software offered by Palantir.
Technical leadership in Greater Manchester highlights several key structural differences between the two frameworks. Matt Hennessey, chief data and analytics officer at NHS Greater Manchester, emphasized that ADSP incorporates primary care data that is entirely absent from the national FDP framework. Furthermore, because ADSP was designed internally as a flexible modular system, specific technical components like data visualization modules can be updated or swapped out whenever superior tools become available. Hennessey also noted that ADSP benefits from deep public trust developed over multiple years of local engagement, encouraging patients to share sensitive health data.
Palantir has disputed claims of ADSP superiority. Stephen Childs, head of healthcare partnerships at Palantir UK, stated that limited independent evidence exists to show ADSP has directly improved patient care or reduced operational costs. Childs added that thousands of medical professionals actively use the FDP across Britain and have publicly documented its operational value. Nevertheless, Greater Manchester’s position has become a central focal point in discussions concerning national data strategy.
Ethical Controversies, Corporate Statements, and Parliamentary Reports
The dispute over the NHS data contract comes amid broader public scrutiny of Palantir’s global activities. Protests, public petitions, parliamentary inquiries, and reported pushback among healthcare workers have intensified due to the firm’s military contracts and involvement in US immigration enforcement actions. Other European governments have similarly begun reevaluating their technology agreements with American firms to reduce strategic dependency during periods of geopolitical friction.
Corporate statements from Palantir leadership have further fueled public debate in Britain. In 2023, Palantir cofounder Peter Thiel suggested that the UK should completely tear down the NHS and rebuild it from scratch. More recently, the company published a detailed corporate manifesto based on writings by chief executive Alex Karp, which one member of parliament publicly characterized as the ramblings of a supervillain. Public health researchers, including Jessica Morley of the Yale University Digital Ethics Center, have argued that Palantir’s corporate philosophy is fundamentally incompatible with the core public service values of the NHS.
Legislative scrutiny has also grown within the UK parliament. In June, a bipartisan group of politicians released a comprehensive report warning that over-reliance on a single foreign technology provider creates an unacceptable systemic vulnerability. The report recommended that the government exercise its break clause to pursue domestic technology solutions. In July, a separate parliamentary committee chaired by MP Layla Moran cited testimony from Greater Manchester officials to conclude that Palantir was not the only viable provider capable of serving NHS needs.
The Impending February Break Clause: Nationwide Scale versus Trust
As the government approaches the February milestone where it can legally terminate the contract early or commit to the full agreement ending in 2031, technical experts remain deeply divided. FDP advocates argue that comparing regional analytics tools like ADSP to the national platform is fundamentally flawed. Tom Bartlett asserted that the national software performs complex operational coordination across hospital trusts and care boards that regional analytics platforms were never designed to execute. Bartlett warned that terminating the contract without a ready replacement could force care providers back to paper-based tracking methods.
Conversely, healthcare leaders in Greater Manchester maintain that public trust and clinician adoption are mandatory prerequisites for any data platform’s operational success. Matt Hennessey argued that even a technically sophisticated platform becomes redundant if clinicians, patients, and data controllers lack confidence in the system. As public scrutiny remains elevated, the debate over whether the NHS should maintain its partnership with Palantir or pivot toward decentralized, domestic platforms continues to shape the future of British healthcare technology governance.
